These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 19583830)

  • 21. Vaccinia virus-mediated expression of human erythropoietin in tumors enhances virotherapy and alleviates cancer-related anemia in mice.
    Nguyen DH; Chen NG; Zhang Q; Le HT; Aguilar RJ; Yu YA; Cappello J; Szalay AA
    Mol Ther; 2013 Nov; 21(11):2054-62. PubMed ID: 23765443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Virotherapy of canine tumors with oncolytic vaccinia virus GLV-1h109 expressing an anti-VEGF single-chain antibody.
    Patil SS; Gentschev I; Adelfinger M; Donat U; Hess M; Weibel S; Nolte I; Frentzen A; Szalay AA
    PLoS One; 2012; 7(10):e47472. PubMed ID: 23091626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Colonization of xenograft tumors by oncolytic vaccinia virus (VACV) results in enhanced tumor killing due to the involvement of myeloid cells.
    Kilinc MO; Ehrig K; Pessian M; Minev BR; Szalay AA
    J Transl Med; 2016 Dec; 14(1):340. PubMed ID: 27993141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation.
    Zhang Q; Liang C; Yu YA; Chen N; Dandekar T; Szalay AA
    Mol Genet Genomics; 2009 Oct; 282(4):417-35. PubMed ID: 19701652
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of a new recombinant oncolytic vaccinia virus strain GLV-5b451 for feline mammary carcinoma therapy.
    Adelfinger M; Gentschev I; Grimm de Guibert J; Weibel S; Langbein-Laugwitz J; Härtl B; Murua Escobar H; Nolte I; Chen NG; Aguilar RJ; Yu YA; Zhang Q; Frentzen A; Szalay AA
    PLoS One; 2014; 9(8):e104337. PubMed ID: 25093734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncolytic vaccinia virus GLV-1h68 exhibits profound antitumoral activities in cell lines originating from neuroendocrine neoplasms.
    Kloker LD; Berchtold S; Smirnow I; Beil J; Krieg A; Sipos B; Lauer UM
    BMC Cancer; 2020 Jul; 20(1):628. PubMed ID: 32631270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in (V600D/E)BRAF mutant melanoma depends on JNK and TNF-α signaling.
    Kyula JN; Khan AA; Mansfield D; Karapanagiotou EM; McLaughlin M; Roulstone V; Zaidi S; Pencavel T; Touchefeu Y; Seth R; Chen NG; Yu YA; Zhang Q; Melcher AA; Vile RG; Pandha HS; Ajaz M; Szalay AA; Harrington KJ
    Oncogene; 2014 Mar; 33(13):1700-12. PubMed ID: 23624923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deciphering the Immunomodulatory Capacity of Oncolytic Vaccinia Virus to Enhance the Immune Response to Breast Cancer.
    Umer BA; Noyce RS; Franczak BC; Shenouda MM; Kelly RG; Favis NA; Desaulniers M; Baldwin TA; Hitt MM; Evans DH
    Cancer Immunol Res; 2020 May; 8(5):618-631. PubMed ID: 32127390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of fractionated irradiation with anti-VEGF expressing vaccinia virus therapy enhances tumor control by simultaneous radiosensitization of tumor associated endothelium.
    Buckel L; Advani SJ; Frentzen A; Zhang Q; Yu YA; Chen NG; Ehrig K; Stritzker J; Mundt AJ; Szalay AA
    Int J Cancer; 2013 Dec; 133(12):2989-99. PubMed ID: 23729266
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer.
    Gholami S; Marano A; Chen NG; Aguilar RJ; Frentzen A; Chen CH; Lou E; Fujisawa S; Eveno C; Belin L; Zanzonico P; Szalay A; Fong Y
    Breast Cancer Res Treat; 2014 Dec; 148(3):489-99. PubMed ID: 25391896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antigen profiling analysis of vaccinia virus injected canine tumors: oncolytic virus efficiency predicted by boolean models.
    Cecil A; Gentschev I; Adelfinger M; Nolte I; Dandekar T; Szalay AA
    Bioengineered; 2014; 5(5):319-25. PubMed ID: 25482233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent.
    Gentschev I; Stritzker J; Hofmann E; Weibel S; Yu YA; Chen N; Zhang Q; Bullerdiek J; Nolte I; Szalay AA
    Cancer Gene Ther; 2009 Apr; 16(4):320-8. PubMed ID: 18949014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel genetically modified oncolytic vaccinia virus in experimental models is effective against a wide range of human cancers.
    Haddad D; Chen N; Zhang Q; Chen CH; Yu YA; Gonzalez L; Aguilar J; Li P; Wong J; Szalay AA; Fong Y
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S665-74. PubMed ID: 22258815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene therapy using therapeutic and diagnostic recombinant oncolytic vaccinia virus GLV-1h153 for management of colorectal peritoneal carcinomatosis.
    Eveno C; Mojica K; Ady JW; Thorek DL; Longo V; Belin LJ; Gholami S; Johnsen C; Zanzonico P; Chen N; Yu T; Szalay AA; Fong Y
    Surgery; 2015 Feb; 157(2):331-7. PubMed ID: 25616946
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of GLV-1h68 for Vaccinia Virotherapy and Monitoring.
    Frentzen A; Geissinger U; Tsoneva D; Stritzker J
    Methods Mol Biol; 2015; 1317():225-37. PubMed ID: 26072410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preferential colonization of metastases by oncolytic vaccinia virus strain GLV-1h68 in a human PC-3 prostate cancer model in nude mice.
    Donat U; Weibel S; Hess M; Stritzker J; Härtl B; Sturm JB; Chen NG; Gentschev I; Szalay AA
    PLoS One; 2012; 7(9):e45942. PubMed ID: 23049897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68.
    Ascierto ML; Worschech A; Yu Z; Adams S; Reinboth J; Chen NG; Pos Z; Roychoudhuri R; Di Pasquale G; Bedognetti D; Uccellini L; Rossano F; Ascierto PA; Stroncek DF; Restifo NP; Wang E; Szalay AA; Marincola FM
    BMC Cancer; 2011 Oct; 11():451. PubMed ID: 22011439
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deletion of
    Potts KG; Irwin CR; Favis NA; Pink DB; Vincent KM; Lewis JD; Moore RB; Hitt MM; Evans DH
    EMBO Mol Med; 2017 May; 9(5):638-654. PubMed ID: 28289079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preferential replication of systemically delivered oncolytic vaccinia virus in focally irradiated glioma xenografts.
    Advani SJ; Buckel L; Chen NG; Scanderbeg DJ; Geissinger U; Zhang Q; Yu YA; Aguilar RJ; Mundt AJ; Szalay AA
    Clin Cancer Res; 2012 May; 18(9):2579-90. PubMed ID: 22379115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new MVA ancestor-derived oncolytic vaccinia virus induces immunogenic tumor cell death and robust antitumor immune responses.
    Rojas JJ; Van Hoecke L; Conesa M; Bueno-Merino C; Del Canizo A; Riederer S; Barcia M; Brosinski K; Lehmann MH; Volz A; Saelens X; Sutter G
    Mol Ther; 2024 Jul; 32(7):2406-2422. PubMed ID: 38734899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.